Drug–Drug Interactions of Cannabidiol with Standard-of-Care Chemotherapeutics
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24032885 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Tereza Buchtova und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University, 77 147 Olomouc, Czech Republic. Hauptthemen laut MEDLINE: Cannabidiol, Cannabinoids, Cannabis, Neoplasms. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 133 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ENOCH, Czech Science Foundation, Internal grant of the University of Palacky.
Abstract (Originalsprache)
Cannabidiol (CBD) is an easily accessible and affordable Marijuana (Cannabis sativa L.) plant derivative with an extensive history of medical use spanning thousands of years. Interest in the therapeutic potential of CBD has increased in recent years, including its anti-tumour properties in various cancer models. In addition to the direct anticancer effects of CBD, preclinical research on numerous cannabinoids, including CBD, has highlighted their potential use in: (i) attenuating chemotherapy-induced adverse effects and (ii) enhancing the efficacy of some anticancer drugs. Therefore, CBD is gaining popularity as a supportive therapy during cancer treatment, often in combination with standard-of-care cancer chemotherapeutics. However, CBD is a biologically active substance that modulates various cellular targets, thereby possibly resulting in unpredictable outcomes, especially in combinations with other medications and therapeutic modalities. In this review, we summarize the current knowledge of CBD interactions with selected anticancer chemotherapeutics, discuss the emerging mechanistic basis for the observed biological effects, and highlight both the potential benefits and risks of such combined treatments. Apart from the experimental and preclinical results, we also indicate the planned or ongoing clinical trials aiming to evaluate the impact of CBD combinations in oncology. The results of these and future trials are essential to provide better guidance for oncologists to judge the benefit-versus-risk ratio of these exciting treatment strategies. We hope that our present overview of this rapidly advancing field of biomedicine will inspire more preclinical and clinical studies to further our understanding of the underlying biology and optimize the benefits for cancer patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University, 77 147 Olomouc, Czech Republic.
- Danish Cancer Society Research Center, DK-2100 Copenhagen, Denmark.
- Department of Medical Biochemistry and Biophysics, Science for Life Laboratory, Division of Genome Biology, Karolinska Institute, 171 77 Stockholm, Sweden.
ORCID-Profile: Zdenek Skrott, Katarina Chroma, Martin Mistrik
Förderung
- ENOCH
- Czech Science Foundation
- Internal grant of the University of Palacky
- Danish National Research Foundation
- European Union - Next Generation EU, National Institute for Cancer Research
- Grant agency of the Czech Republic
- the Danish National Research Foundation
- project National Institute for Cancer Research
Zitieren
APA
Buchtova, T., Lukac, D., Skrott, Z., Chroma, K., Bartek, J., & Mistrik, M. (2023). Drug–Drug Interactions of Cannabidiol with Standard-of-Care Chemotherapeutics. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24032885
Vancouver
Buchtova T, Lukac D, Skrott Z, Chroma K, Bartek J, Mistrik M. Drug–Drug Interactions of Cannabidiol with Standard-of-Care Chemotherapeutics. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24032885
BibTeX
@article{Buchtova2023,
author = {Buchtova, Tereza and Lukac, David and Skrott, Zdenek and Chroma, Katarina and Bartek, Jiri and Mistrik, Martin},
title = {Drug–Drug Interactions of Cannabidiol with Standard-of-Care Chemotherapeutics},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24032885}
}
EUVIMED